中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial

文献类型：期刊论文

作者Ni, Li1,2; Wen, Zheng1,2; Hu, Xiaowen3; Tang, Wei4; Wang, Haisheng5; Zhou, Ling1,2; Wu, Lujin1,2; Wang, Hong1,2; Xu, Chang1,2; Xu, Xizhen1,2
刊名FRONTIERS OF MEDICINE
出版日期2021-04-28
页码14
ISSN号2095-0217
关键词COVID-19 SARS-CoV-2 Shuanghuanglian oral liquid clinical trial
DOI10.1007/s11684-021-0853-6
通讯作者Zuo, Jianping(jpzuo@simm.ac.cn) ; Weng, Jianping(wengjp@ustc.edu.cn) ; Jiang, Hualiang(hljiang@simm.ac.cn) ; Wang, Dao Wen(dwwang@tjh.tjmu.edu.cn)
英文摘要We conducted a randomized, open-label, parallel-controlled, multicenter trial on the use of Shuanghuanglian (SHL), a traditional Chinese patent medicine, in treating cases of COVID-19. A total of 176 patients received SHL by three doses (56 in low dose, 61 in middle dose, and 59 in high dose) in addition to standard care. The control group was composed of 59 patients who received standard therapy alone. Treatment with SHL was not associated with a difference from standard care in the time to disease recovery. Patients with 14-day SHL treatment had significantly higher rate in negative conversion of SARS-CoV-2 in nucleic acid swab tests than the patients from the control group (93.4% vs. 73.9%, P = 0.006). Analysis of chest computed tomography images showed that treatment with high-dose SHL significantly promoted absorption of inflammatory focus of pneumonia, which was evaluated by density reduction of inflammatory focus from baseline, at day 7 (mean difference (95% CI), -46.39 (-86.83 to -5.94) HU; P = 0.025) and day 14 (mean difference (95% CI), -74.21 (-133.35 to -15.08) HU; P = 0.014). No serious adverse events occurred in the SHL groups. This study illustrated that SHL in combination with standard care was safe and partially effective for the treatment of COVID-19.
资助项目National Key R&D Program of China[2020YFC0841400] ; Tongji Hospital Clinical Research Project[XXGZBDYJ009] ; Tongji Hospital Clinical Research Project[2019YBKY019]
WOS研究方向Oncology ; Research & Experimental Medicine
语种英语
出版者SPRINGER
WOS记录号WOS:000645191000003
源URL[http://119.78.100.183/handle/2S10ELR8/297395]  
专题新药研究国家重点实验室
通讯作者Zuo, Jianping; Weng, Jianping; Jiang, Hualiang; Wang, Dao Wen
作者单位1.Huazhong Univ Sci & Technol, Div Cardiol, Dept Internal Med, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Peoples R China
2.Huazhong Univ Sci & Technol, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China
3.Univ Sci & Technol China, Affiliated Hosp 1, Hefei 230026, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
5.Harbin Pharmaceut Grp Co Ltd, Harbin 150070, Peoples R China
6.Sixth Hosp Harbin, Harbin 150036, Peoples R China
7.Nanjing Univ Chinese Med, Second Hosp Nanjing, Nanjing 210003, Peoples R China
8.Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing 210003, Peoples R China
9.Chinese Peoples Liberat Army Cent War Command Gen, Dept Cardiol, Wuhan 430010, Peoples R China
10.Huazhong Univ Sci & Technol, Dept Informat Management, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China
推荐引用方式
GB/T 7714		 Ni, Li,Wen, Zheng,Hu, Xiaowen,et al. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial[J]. FRONTIERS OF MEDICINE,2021:14.
APA Ni, Li.,Wen, Zheng.,Hu, Xiaowen.,Tang, Wei.,Wang, Haisheng.,...&Wang, Dao Wen.(2021).Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial.FRONTIERS OF MEDICINE,14.
MLA Ni, Li,et al."Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial".FRONTIERS OF MEDICINE (2021):14.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。